BioSpace News Archive

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

iCAD, Inc. announced that new research supporting ProFound AI® for Digital Breast Tomosynthesis will be presented at the Society of Breast Imaging Breast Imaging Symposium, taking place May 16-19 in Savannah, GA.

Veloxis Pharmaceuticals, Inc. , an Asahi Kasei company, today announced that the first participant has been dosed in a Phase 1 Study of VEL-101 [ NCT05238493 ]. VEL-101 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

US Radiology Specialists, Inc., one of the nation’s premier physician-owned radiology companies, announced that it is partnering with Volpara Health to implement the latest breast density assessment, mammography reporting, and patient communication software at Charlotte Radiology.

Laekna Therapeutics (" Laekna "), a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases, announced that it has raised $61 million in Series D financing led by CS Capital with support from Worldstar, and Infinity Capital.

Cytovia Therapeutics, LLC (“Cytovia Therapeutics”), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the the Annual European Hematology Association’s (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Charles M. Baum , M.D., Ph.D., to its Board of Directors, effective May 16, 2022.

BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”) has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company’s autologous haptenized tumor cell vaccine for late-stage ovarian cancer.

Alcyone Therapeutics Inc. (“Alcyone”), a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions, today presents preclinical data showing the Company’s partnered novel adeno associated virus serotype 9 (AAV9) gene therapy vector ACTX-101.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), today announced it has received a Notice of Allowance for U.S. patent application number 16/833,515 from the United States Patent and Trademark Office (USPTO) covering SLS-007 titled: “Structure-Based Peptide Inhibitors of Alpha-Synuclein Aggregation”.